PRIVATE LAB BRIEFS

SCID Mice Go Commercial The Philadelphia-based Fox Chase Cancer Center has entered the mutant mouse business with a series of licensing agreements that will allow commercial distribution of a key strain used to study diseases of the immune system. The SCID (severe combined immune deficiency) strain, which arose naturally from a chance mating of two normal mice in the Fox Chase labs in 1981, was the first to accept human immune system cells, making national headlines for two California research

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Philadelphia-based Fox Chase Cancer Center has entered the mutant mouse business with a series of licensing agreements that will allow commercial distribution of a key strain used to study diseases of the immune system. The SCID (severe combined immune deficiency) strain, which arose naturally from a chance mating of two normal mice in the Fox Chase labs in 1981, was the first to accept human immune system cells, making national headlines for two California research teams (The Scientist, Oct. 31, 1988, page 1). Because the mutation is naturally occurring, Fox Chase is prohibited from patenting the mouse, but careful conservation of the strain has allowed it to be trademarked. Samuel Phalen, marketing director of Taconic Farms Inc. of Germantown, N.Y., which will U.S. and Canada, says that he hopes to begin shipments by April of next year. As part of its agreement with the licensing firms—a Danish firm and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies